CURRICULUM VITAE

Full Name:	Leon	Ramon	
	Last Name	First Name	Middle Initial

Professional Mailing Address: (Include institution name.)

IMIC Inc
18320 Franjo Rd (aka SW 97 Ave)
Palmetto Bay FL 33157

Telephone: 786-310-7477/ fax 305-252-2199, email: ramon@aktamedika.com

Academic Qualifications (most current date first)

Degree/Certification	Date (YYYY)	Institution, Country
GCP Course	2015	CITI
Specialist Family Medicine	2007	American Board of Family Medicine
Residency Family Medicine	2005	St Mary of Nazareth Hospital, Chicago, IL- Residency
Medical Doctor	1991	Instituto Superior de Sciencias Medicas, Havana Cuba

Current and Previous 4 Relevant Positions Including Academic Appointments (most current date first):

Start and End Dates	Title	Institution or Company, State/Province/Country
2013-current	Principal Investigator/ Sub-I/ Medical Director	IMIC, Inc
2011-2013	Sub-I/research consultant	Akta Medika
2007 - current	Family Physician, Partner	South Dade Primary Care Inc, Miami FL

Brief Summary of Relevant Clinical Research Experience in the last 5 years:

2017-IDN-6556-17: A Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial of Emricasan, an Oral Caspase Inhibitor, in Subjects with Decompensated Non-Alcoholic Steatohepatitis (NASH) Cirrhosis as SI
2017-Protocol No. GS-US-384-1944: A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Safety and Efficacy of Selonsertib in Subjects with Compensated Cirrhosis due to Nonalcoholic Steatohepatitis (NASH) as SI
E2609-G000-302: A Placebo-Controlled, Double-Blind, Parallel-Group, 24-Month Study to Evaluate the Efficacy and Safety of E2609 in Subjects with Early Alzheimer's Disease as Sub-I
2016-E5501-G000-310: A Randomized, Global, Double-blind, Placebo-controlled, Parallel-group Study to Evaluate the Efficacy and Safety of Once-daily Oral Avatrombopag for the Treatment of Adults with Thrombocytopenia Associated with Liver Disease Prior to an Elective Procedure as SI
2016 – Double-blind, Randomized, Placebo-controlled, Parallel-group, Phase IV Study to Evaluate the Effect of Aclidinium Bromide on Long-term Cardiovascular Safety and COPD Exacerbations in Patients with Moderate to Very Severe COPD (ASCENT COPD) LAS-MD-45 (D6560C00002) as PI
2016 - A Phase 2b Double-Blind, Multi-Dose, Placebo-Controlled Study to Evaluate the Efficacy and Safety of MEDI2070 in Subjects with Moderate to Severe Crohn's Disease Who Have Failed or Are Intolerant to Anti-Tumor Necrosis Factor-Alpha Therapy as SI
2016 - BLI400-303: An Open Label Study of Chronic Use of BLI400 Laxative in Constipated Adults as SI
2016 - GA28951: AN OPEN-LABEL EXTENSION AND SAFETY MONITORING STUDY OF MODERATE TO SEVERE ULCERATIVE COLITIS PATIENTS PREVIOUSLY ENROLLED IN ETROLIZUMAB PHASE III STUDIES as SI
2016- Randomized, 16-Week, Multi-Phase, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Tolerability of Fulranumab as Adjunctive Therapy in Subjects with Signs and Symptoms of Osteoarthritis of the Hip or Knee as PI
2016 - A randomized, double-blind, placebo controlled study to evaluate the safety, tolerability and clinical effect of oral danirixin (GSK1325756) in the treatment of healthy adults with acute, uncomplicated influenza (201682) as PI
2016 - 15-AVP-786-302: A Phase 3, multicenter, randomized, double-blind, placebo-controlled study to assess the efficacy, safety, and tolerability of AVP-786 (deuterated [d6]-dextromethorphan hydrobromide [d6-DM]/quinidine sulfate [Q]) for the treatment of agitation in patients with dementia of the Alzheimer's type as SI
2015 - 000175 -A Randomized, Double-Blind, Placebo-Controlled, Multicenter Study Investigating the Efficacy and Safety of Mesalamine 2 g Extended Release Granules (Sachet) for Maintenance of Clinical and Endoscopic

Remission in Ulcerative Colitis as SI
2015 - M13-740 -A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study of ABT-494 for the Induction of Symptomatic and Endoscopic Remission in Subjects with Moderately to Severely Active Crohn's Disease who have Inadequately Responded to or are Intolerant to Anti-TNF Therapy as SI
2015 - Daiichi Sankyo, Protocol *DS-5565-A-U305 – Diabetic Peripheral Neuropathic Pain as SI*
2015 - A Randomized, Double-Blind, Placebo Controlled, 13-Week Study of DS-5565 for Treatment of Diabetic Peripheral Neuropathic Pain.DS5565-A-U308 as SI
2015 - Clinical Trial of SB-509 in Subjects With Diabetic Neuropathy As PI

2015 - 000174 - A Randomized, Double-Blind, Placebo-Controlled, Multicenter Study Investigating the Efficacy and Safety of Mesalamine 4 g Extended Release Granules (Sachet) for the Induction of Clinical and Endoscopic Remission in Active, Mild to Moderate Ulcerative Colitis as SI

2015- A Phase 2, Multicenter, Randomized, Double-blind, Placebo-controlled Dose-ranging Study of Vapendavir in Moderate to Severe Asthmatic Adults with Symptomatic Human Rhinovirus Infection as PI
2014- A 24-month, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group, Efficacy, Safety, Tolerability, Biomarker, and Pharmacokinetic Study of AZD3293 in Outpatients with Early Alzheimer's Disease as Sub-I
2015- phase 3 - A 52-Week, Multicentre, Randomized, Double-Blind, Parallel Group, Placebo Controlled, Phase 3 Study to Evaluate the Efficacy and Safety of Tralokinumab in Adults and Adolescents with Asthma Inadequately Controlled on Inhaled Corticosteroid Plus Long-Acting β_2-Agonist (STRATOS 2) as PI
2015 - GT-026: A Multicenter, Randomized, Placebo-Controlled, Double-Blind, Parallel-Group, Phase 2 Clinical Trial to Evaluate the Safety and Efficacy of GR-MD-02 for the Treatment of Liver Fibrosis and Resultant Portal Hypertension in Patients with NASH Cirrhosis. The NASH-CX Trial as SI
2014 - A RANDOMIZED, DOUBLE-BLIND, PLACEBO- AND ACTIVE-CONTROLLED STUDY OF DS-5565 IN SUBJECTS WITH PAIN ASSOCIATED WITH FIBROMYALGIA as PI
2014- An Efficacy and Safety Study of Sustained-release Paracetamol in Subjects with Osteoarthritis as PI
2014 – Phase 1 OTT329/305: CLINICAL ENDPOINT STUDY OF SALMETEROL XINAFOATE/FLUTICASONE PROPIONATE COMBINATION FOR COMPARISON OF A TEST AND REFERENCE PRODUCT IN PATIENTS WITH ASTHMA AS PI
2014 - A randomized, double-blind, placebo-controlled, dose-ranging, multicenter study to assess the efficacy and safety of rifaximin soluble solid dispersion (SSD) tablets for the prevention of complications in subjects with early decompensated liver cirrhosis as Sub-I
2014 – Phase 1, A Randomized, Parallel-Group, Placebo-Controlled, Clinical Endpoint Bioequivalence Study of Generic Fluticasone Propionate 100 µg and Salmeterol Xinafoate 50 µg Inhalation Powder Compared with Advair Diskus® 100/50 in Subjects with Asthma, FLSA-P100/50-PVCL as PI
2014-Polyherbal capsule formulation for joint health: a multicenter, 2-arm, randomized, double-blind, placebo-controlled study as PI
2014- A randomized, double-blind, placebo-controlled, 13-week study of ds-5565 for treatment of diabetic peripheral neuropathic pain as PI
2013 – Phase 2, Treatment of Neuropathic Pain Associated With Diabetic Peripheral Neuropathy as SI
2013- A randomized double-blind placebo controlled parallel group study of the efficacy and safety of pregabalin (bid) in subjects with post-traumatic peripheral neuropathic pain as PI

2013- MKC-TI-134, A Phase 3, Multicenter, Open-label, Randomized Clinical Trial to Evaluate the Safety of Technosphere® Insulin Inhalation Powder in Type 1 or Type 2 Diabetic Subjects with Obstructive Pulmonary Disease (Asthma or Chronic Obstructive Pulmonary Disease) Over a 12-month Treatment Period with a 2-month Follow-up as SI
2013- A Randomized, 4-Week, Double-Blind, Placebo-Controlled, Dose-Ranging Study to Assess the Safety and Efficacy of SP-333 for the Treatment of Opioid-induced Constipation (OIC) in Patients with Non-malignant Chronic Pain Receiving Opioid Therapy as SI
2013- Dey Protocol 191-091: Phase II - A 12-week Randomized, Multiple-Dose, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate Nebulized Fluticasone Propionate (FP) Dose Response in Adult Subjects with Partly Controlled and Uncontrolled Asthma as PI
2013 - DECLARE-TIMI 58 study (Dapagliflozin Effect on CardiovascuLAR Events) as Sub-I
2013 - Phase II - A 12-week Randomized, Multiple-Dose, Double-Blind, Placebo-Controlled, Parallel-Group Study to Replicate Efficacy of Nebulized Fluticasone Propionate (FP) in Adult Subjects with Partly Controlled and Uncontrolled Asthma as PI

2013 – Phase 4 - A 26 week, randomized, double-blind, parallel-group, active controlled, multicenter, multinational safety study evaluating the risk of serious asthma-related events during treatment with Symbicort®, a fixed combination of inhaled corticosteroid (ICS) (budesonide) and a long acting β2-agonist (LABA) (formoterol) as compared to treatment with ICS (budesonide) alone in adult and adolescent (≥12 years of age) patients with asthma as PI

2013 - A Placebo-Controlled, Double-Blind, Parallel, Randomized, Clinical Dose-Confirming Study of Pulsed, Inhaled Nitric Oxide (iNO) in Subjects with World Health Organization (WHO) Group 3Pulmonary Hypertension (PH) Associated with Chronic Obstructive Pulmonary Disease (COPD) on Long-Term Oxygen Therapy (LTOT) as SI

2013-Blacks and Exacerbations on Long Acting Beta Agonists (LABA) vs. Tiotropium (BELT, Harvard) as PI

2012-MB102073: A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel Group, Phase 3 Trial to Evaluate the Safety and Efficacy of Dapagliflozin in Subjects with Type 2 Diabetes with inadequately controlled hypertension on an Angiotensin-Converting Enzyme Inhibitor (ACEI) or Angiotensin Receptor Blocker (ARB) as Sub-I

2012-MB102077: A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel Group, Phase 3 Trial to Evaluate the Safety and Efficacy of Dapagliflozin in Subjects with Type 2 Diabetes with inadequately controlled hypertension treated with an Angiotensin-Converting Enzyme Inhibitor (ACEI) or Angiotensin Receptor Blocker (ARB) and an additional Antihypertensive medication as Sub-I

2012- Study To Evaluate The Efficacy And Safety Of PH-797804 For 12 Weeks In Adults With Moderate To Severe Chronic Obstructive Pulmonary Disease (COPD) On A Background Of Tiotropium Bromide as Sub-I

2011- Study To Evaluate The Efficacy And Safety Of PH-797804 For 12 Weeks In Adults With Moderate To Severe Chronic Obstructive Pulmonary Disease (COPD) Taking Salmeterol Xinafoate/Fluticasone Propionate Combination as Sub-I

2011- Efficacy and Safety in Patients With Type 2 Diabetes Mellitus and Cardiovascular Disease as Sub-I

2011-phase 3 - Efficacy of CHF1535 Via NEXT DPI Versus pMDI and BDP DPI100µg on PeakExpiratoryFlow in Asthmatic Patients (Neptune), as Sub-I

Medical License: ME92409/ exp 01/31/2019	**FL/USA**
Signature: 	**Signature Date:** 26/May/2017